This article discusses calcitonin as an alternative for patients with established osteoporosis who cannot, will not, or should not proceed with estrogen replacement therapy. Clinical trial data for calcitonin in both injectable and nasal spray formulations and for both lower-dose and higher-dose regimens are presented.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0889-8529(05)70013-x | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!